Ivacaftor

Orphan designation: (6aR,10aR)-3-(1',1'-dimethylheptyl)-delta-8-tetrahydrocannabinol-9-carboxylic acid- Treatment of cystic fibrosis, 14/10/2016 Withdrawn

Retrieved on: 
Thursday, April 18, 2024
Eurostat, Diagnosis, Civil service commission, Absorption, Lower respiratory tract infection, Exercise, Cell, Infection, DSM-IV codes, Inflammation, Patient, Committee, Cystic fibrosis, Knowledge, Digestion, Regulation, Bacteria, Food, EMA, IRIS, Anti-inflammatory, Mucus, CB2, European, COMP, Pancreas, Sponsor, Ivacaftor, European Commission, Safety, CFTR, Marketing, Medicine, Pharmaceutical industry

Orphan designation: (6aR,10aR)-3-(1',1'-dimethylheptyl)-delta-8-tetrahydrocannabinol-9-carboxylic acid- Treatment of cystic fibrosis, 14/10/2016 Withdrawn

Key Points: 


Orphan designation: (6aR,10aR)-3-(1',1'-dimethylheptyl)-delta-8-tetrahydrocannabinol-9-carboxylic acid- Treatment of cystic fibrosis, 14/10/2016 Withdrawn

Orphan designation: (6aR,10aR)-3-(1',1'-dimethylheptyl)-delta-8-tetrahydrocannabinol-9-carboxylic acid- Treatment of cystic fibrosis, 14/10/2016 Positive

Retrieved on: 
Tuesday, April 9, 2024
Eurostat, Diagnosis, Civil service commission, Absorption, Lower respiratory tract infection, Exercise, Cell, Infection, DSM-IV codes, Inflammation, Patient, Committee, Cystic fibrosis, Knowledge, Digestion, Regulation, Bacteria, Food, EMA, IRIS, Anti-inflammatory, Mucus, CB2, European, COMP, Pancreas, Sponsor, Ivacaftor, European Commission, Safety, CFTR, Marketing, Medicine, Pharmaceutical industry

Orphan designation: (6aR,10aR)-3-(1',1'-dimethylheptyl)-delta-8-tetrahydrocannabinol-9-carboxylic acid- Treatment of cystic fibrosis, 14/10/2016 Positive

Key Points: 


Orphan designation: (6aR,10aR)-3-(1',1'-dimethylheptyl)-delta-8-tetrahydrocannabinol-9-carboxylic acid- Treatment of cystic fibrosis, 14/10/2016 Positive

Arcturus Therapeutics Announces Third Quarter 2023 Financial Update and Pipeline Progress

Retrieved on: 
Tuesday, November 14, 2023
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, CSL, Safety, Research, DNA, Ornithine transcarbamylase deficiency, Therapy, Cystic fibrosis, Technology transfer, Liver, Clinical trial, Database, COVID-19, Patient, FDA, PMDA, Vaccine, ARCT, Messenger, Valencia CF Foundation, Arcturus Therapeutics, Conference, RNA, Ferret, Infection, Ivacaftor, CFTR, OTC, Government, HIV disease progression rates, Transfection, Travel, COVID, Pharmaceutical industry, Cryptocurrency, Arcturus

“We had considerable progress this quarter expanding our next generation STARR® vaccine platform,” said Joseph Payne, President & CEO of Arcturus Therapeutics.

Key Points: 
  • “We had considerable progress this quarter expanding our next generation STARR® vaccine platform,” said Joseph Payne, President & CEO of Arcturus Therapeutics.
  • ARCALIS Inc., the Company’s manufacturing joint venture in Japan to support the production of mRNA vaccines and therapeutics, continues to make operational progress while also obtaining financial support from the Japanese government.
  • Arcturus achieved a milestone for $35 million and anticipates receipt from CSL in November 2023.
  • Arcturus expects the final database lock to occur in the fourth quarter of 2023.

Royalty Pharma Reports Second Quarter 2023 Results

Retrieved on: 
Tuesday, August 8, 2023
Acceleration, Net, Pressure, University, Civil service commission, Astellas Pharma, Chronic lymphocytic leukemia, Vertex, Calendar, Aplastic anemia, DPP, GAAP, Leuprorelin, Sale, Ulcerative colitis, Psoriasis, Gilead, EBITDA, Acquisition, European Commission, Patient, Risk, Metastasis, Cystic fibrosis, Growth, Johnson & Johnson, California Miramar University, FDA, Sacituzumab govitecan, Regulation of tobacco by the U.S. Food and Drug Administration, Death, Food, Ivacaftor, Pfizer, Talazoparib, Bank, Video game, Music, Vaccine, Pharmaceutical industry, Real estate, Cryptocurrency, Berotralstat, Apalutamide, Nusinersen, Elexacaftor/tezacaftor/ivacaftor, Adjustment, Guselkumab, Ibrutinib

Drivers of total royalty receipts in the second quarter of 2023 are discussed below, based on commentary from the marketers of the products underlying the royalties in the preceding quarter (as royalty receipts generally lag product performance by one calendar quarter).

Key Points: 
  • Drivers of total royalty receipts in the second quarter of 2023 are discussed below, based on commentary from the marketers of the products underlying the royalties in the preceding quarter (as royalty receipts generally lag product performance by one calendar quarter).
  • Royalty Pharma acquired a royalty interest in Trelegy in July 2022 and began receiving royalty receipts in the third quarter of 2022.
  • During the second quarter of 2023, Royalty Pharma began repurchasing its Class A ordinary shares and repurchased approximately four million shares for $134 million.
  • The weighted-average diluted Class A ordinary shares outstanding for the second quarter of 2023 was 606 million as compared to 607 million for the first quarter of 2023.

Royalty Pharma Announces Expansion of Senior Leadership Team

Retrieved on: 
Thursday, December 15, 2022
Hematological Cancer Research Investment and Education Act, Fluticasone furoate/umeclidinium bromide/vilanterol, Vertex, Republican State Leadership Committee, Sale, Human capital, Natalizumab, AbbVie, Investment, Research, Senior, Publication, Royalty Pharma, EDGAR, Management, Ivacaftor

NEW YORK, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the expansion of its senior leadership team.

Key Points: 
  • NEW YORK, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the expansion of its senior leadership team.
  • This expansion highlights Royalty Pharma’s success in developing a talented, diverse and experienced leadership team responsible for formulating and executing on its mission to accelerate innovation and transform patient lives.
  • Brienne has been a key member of the Research & Investments team since joining Royalty Pharma in 2014.
  • Alessandra joined Royalty Pharma in 2020 and is responsible for overseeing Royalty Pharma’s human resource planning, professional development and performance management.

Royalty Pharma to Present at Evercore ISI 5th Annual HealthCONx Virtual Conference

Retrieved on: 
Monday, November 28, 2022
Evercore, Royalty Pharma, Conference, AbbVie, Fine chemical, Ivacaftor

NEW YORK, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to participate in a fireside chat at the Evercore ISI 5th Annual HealthCONx Virtual Conference on November 30, 2022 at 10:30 a.m.

Key Points: 
  • NEW YORK, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to participate in a fireside chat at the Evercore ISI 5th Annual HealthCONx Virtual Conference on November 30, 2022 at 10:30 a.m.
  • The webcast will be accessible from Royalty Pharmas Events page at https://www.royaltypharma.com/investors/news-and-events/events .
  • The webcast will also be archived for a minimum of thirty days.
  • Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industrys leading therapies.

Royalty Pharma Agrees to Acquire Royalty Interest in Olpasiran From Arrowhead for $250 million and Future Milestones

Retrieved on: 
Wednesday, November 9, 2022
Molecule, GLOBE, Private Securities Litigation Reform Act, Forward-looking statement, Trim, Royalty Pharma, The New England Journal of Medicine, U.S. Securities and Exchange Commission, Cardiovascular disease, Gene silencing, Nasdaq, Gibson, Dunn & Crutcher, Research, Risk, Moyamoya disease, Gene, EDGAR, Sale, Death, RNA interference, RNA, Annual report, News, Achievement, Safety, Arrowhead Pharmaceuticals, Sirna, Publication, Fenwick & West, Terminology, Patient, NEW, Therapy, Security (finance), Lipoprotein(a), American Heart Association, Armin Maiwald, OCEAN, AbbVie, COVID-19, Pharmaceutical industry, Fine chemical, Amgen, Arrowhead, Ivacaftor

NEW YORK and PASADENA, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Arrowhead today announced that Royalty Pharma has acquired a royalty interest in Amgen’s olpasiran from Arrowhead Pharmaceuticals (Nasdaq: ARWR) for $250 million in cash upfront plus up to $160 million in additional payments contingent on the achievement of certain clinical, regulatory, and sales milestones.

Key Points: 
  • Olpasiran is a small interfering RNA (siRNA) originally developed by Arrowhead using its proprietary Targeted RNAi Molecule, or TRiM, platform and licensed to Amgen in 2016.
  • Cardiovascular disease remains the most common cause of death worldwide despite certain treatment advances, and new therapeutic targets are greatly needed.
  • Royalty Pharma is acquiring Arrowheads entire royalty interest in olpasiran, which is a royalty up to the low double digits on worldwide net sales.
  • Arrowhead will retain rights to the $400 million in development, regulatory and sales milestone payments potentially due from Amgen.

Arrowhead Sells Royalty Interest in Olpasiran to Royalty Pharma for $250 Million and Future Milestones

Retrieved on: 
Wednesday, November 9, 2022
Cardiology, Biotechnology, Pharmaceutical, Finance, Health, Professional Services, Genetics, Clinical Trials, Molecule, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Private Securities Litigation Reform Act, Forward-looking statement, Trim, Royalty Pharma, The New England Journal of Medicine, U.S. Securities and Exchange Commission, Cardiovascular disease, Gene silencing, Gibson, Dunn & Crutcher, Nasdaq, Research, Risk, EDGAR, Moyamoya disease, Gene, Sale, Death, Arrowhead Pharmaceuticals, COVID-19, RNA interference, RNA, Annual report, NASDAQ, News, Achievement, Safety, Sirna, Company, Publication, Fenwick & West, Terminology, Patient, Therapy, Security (finance), Lipoprotein(a), American Heart Association, Armin Maiwald, OCEAN, AbbVie, Fine chemical, Pharmaceutical industry, Amgen, Arrowhead, Ivacaftor

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) and Royalty Pharma plc (Nasdaq: RPRX) today announced that Royalty Pharma has acquired a royalty interest in Amgens olpasiran from Arrowhead for $250 million in cash upfront plus up to $160 million in additional payments contingent on the achievement of certain clinical, regulatory, and sales milestones.

Key Points: 
  • Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) and Royalty Pharma plc (Nasdaq: RPRX) today announced that Royalty Pharma has acquired a royalty interest in Amgens olpasiran from Arrowhead for $250 million in cash upfront plus up to $160 million in additional payments contingent on the achievement of certain clinical, regulatory, and sales milestones.
  • Olpasiran is a small interfering RNA (siRNA) originally developed by Arrowhead using its proprietary Targeted RNAi Molecule, or TRiM, platform and licensed to Amgen in 2016.
  • Royalty Pharma is acquiring Arrowheads entire royalty interest in olpasiran, which is a royalty up to the low double digits on worldwide net sales.
  • Arrowhead will retain rights to the $400 million in development, regulatory, and sales milestone payments potentially due from Amgen.

Royalty Pharma to Announce Third Quarter 2022 Financial Results on November 8, 2022

Retrieved on: 
Tuesday, October 18, 2022
GLOBE, Webcast, Royalty Pharma, AbbVie, Nasdaq, Fine chemical, Ivacaftor

NEW YORK, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its third quarter 2022 financial results on Tuesday, November 8, 2022 before the U.S. financial markets open.

Key Points: 
  • NEW YORK, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its third quarter 2022 financial results on Tuesday, November 8, 2022 before the U.S. financial markets open.
  • The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day.
  • Please visit the Investors page of the companys website at https://www.royaltypharma.com/investors/news-and-events/events to obtain conference call information and to view the live webcast.
  • Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industrys leading therapies.

Royalty Pharma Declares Fourth Quarter 2022 Dividend

Retrieved on: 
Monday, October 17, 2022
GLOBE, Royalty Pharma, AbbVie, Nasdaq, Holding company, Fine chemical, Ivacaftor

NEW YORK, Oct. 17, 2022 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2022 of $0.19 per Class A ordinary share.

Key Points: 
  • NEW YORK, Oct. 17, 2022 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2022 of $0.19 per Class A ordinary share.
  • The dividend will be paid on December 15, 2022, to shareholders of record at the close of business on November 18, 2022.
  • Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies.
  • Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industrys leading therapies.